Best of ASCO 2024 | Hybrid Event in Greece

62
Speakers
2
Days
127
Registrations
15
Sponsors
Τα πιστοποιητικά είναι διαθέσιμα!
Δεν υπάρχουν διαθέσιμα δεδομένα. Επικοινωνήστε μαζί μας μέσω email ζητώντας την πιστοποίησή σας ή καλέστε μας για να σας βοηθήσουμε.

Welcome and Chairs Remarks A. Kotsakis

Chairs: N. Tsoukalas, D. Papageorgiou
12.00-12.20
LBA 3 | Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer.
Abstract 12016 | Identifying optimized assessment of nerve damage during chemotherapy.
M. Lavdaniti

12.20-12.40
Abstract 12020 | A randomized, double-blind controlled trial of medicinal cannabis vs placebo for symptom management in patients with advanced cancer receiving palliative care.
LBA 12004 | Alliance A222001: A randomized, double-blind, placebo controlled phase II study of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy.
C. Ntola

12.40-13.00 Discussion Ν. Tsoukalas, D. Papageorgiou

Chairs: A. Kotsakis, G. Rigakos

13.00-13.30
Abstract 6009 | Long-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.
Abstract 6008 | A randomized, double-blind, placebo-controlled phase II study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for recurrence: The PATHWay study.
LBA 6000 | Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.
P. Katsaounis

13.30-14.00 Discussant A. Psyrri

Chairs: C. Kosmas, C. Panopoulos

State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care.
A. Stribakos

Discussion

Chairs: E. Razis, S. Labropoulos

15.40-16.10
Abstract 2000 | N2M2/NOA-20: Phase I/IIa umbrella trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation.
Abstract 2013 | A phase II trial of olaparib and durvalumab in patients with recurrent IDH-mutated gliomas.
Abstract 2002 | Niraparib efficacy in patients with newly diagnosed glioblastoma: Clinical readout of a phase 0/2 “trigger” trial.
D. Kalapanida

16.10-16.30 Discussant E. Razis

Chairs: A. Psyrri, F. Koinis

16.30-16.50
LBA 2509 | Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial Abstract 2500 | Lete-cel in patients with synovial sarcoma or myxoid/round cell liposarcoma: Planned interim analysis of the pivotal IGNYTE-ESO trial.
S. Talagani

16.50-17.10
Abstract 2504 | Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: Results from phase 1/2 studies.
Abstract 2506 | Phase 1/2 study of the TGF-β-trap-enhanced oncolytic adenovirus, AdAPT-001, plus an immune checkpoint inhibitor for patients with immune refractory cancers.
G. Ardavanis-Loukeris

17.10-17.30 Discussant E. Kontopodis

Chairs: A. Koutras, I. Kotteas

17.50-18.10
LBA 500 |A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy
LBA 502 | A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY Trial.
K. Rapti

18.10-18.30
LBA 507 | Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
Abstract 505 | Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER)
E. Chantzara

18.30-18.50 Discussant A. Nikolaidi

Chairs: V. Barbounis, E. Galani

18.50-19.10
LBA 1001 | Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 post-MONARCH trial
LBA 1002 | Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2- metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL.
C. Aidarinis

19.10-19.40
Abstract 1007 | Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD).
LBA 1000 | Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06)
Abstract 1021 | Τrastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD).
N. Asimakopoulou

19.40- 20.00 Discussant E. Saloustros

Chairs: C. Panopoulos, V. Papadopoulos

09.00-09.20
LBA 3501 | Surgery versus thermal ablation for small-size colorectal liver metastases (COLLISION): An international, multicenter, phase III randomized controlled trial. Abstract 3500 | Chemotherapy and liver transplantation versus chemotherapy alone in patients with definitively unresectable colorectal liver metastases: A prospective multicentric randomized trial (TRANSMET).
Ν. Machairas

09.20-09.40
Abstract 108 | Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: Overall survival and updated 5-year results from the randomized DYNAMIC trial.
Abstract 3503 | Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW.
Μ. Avgoustidou

09.40-10.00 Discussion V. Papadopoulos

Chairs: I. Samaras, Μ. Theochari

10.00-10.20
LBA 1 | Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial). LBA 4008 | Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): first results from CheckMate 9DW.
M. Drizou

10.20-10.40
Abstract 4005 | NRG Oncology/RTOG 0848: Results after adjuvant chemotherapy +/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA).
Abstract 4003 | A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186.
A. Markou

10.40-11.00 Discussant G. Papaxoinis

Chairs: C. Cosmas, P. Katsaounis

Unlocking the Potential: Biomarkers of Response to Antibody - Drug Conjugates V. Papadopoulos

Discussion

Chairs: E. Goga, A. Tzovaras

12.00-12.20
LBA 2 | Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.
LBA 9512 | Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial.
A. Laskarakis

12.20-12.40
Abstract 9500 | Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study LBA 9503 | Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN).
D. Ziogas

12.40-13.00 Discussant D. Bafaloukos

Chairs: A. Boutis, E. Saloustros

13.00-13.30
Abstract 10503 | Clinical behavior of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing: Results from an international cohort study.
Abstract 10506 | Menopausal hormone therapy and ovarian and endometrial cancers: Long-term follow-up of the Women’s Health Initiative randomized trials.
Abstract 10512 | Real-world cancer care utilization among patients with breast cancer with germline variants of uncertain significance.
A. Mala

13.30-13.40 Panel discussion

Chairs: C. Papadimitriou, M. Liontos

14.30-14.50
Abstract 5504 | Adjuvant chemotherapy following concurrent chemoradiation (CRT) in patients with high-risk early- stage cervical carcinoma following radical hysterectomy: Results of NRG oncology / RTOG 0724/GOG-0724.
Abstract 5511 | A phase II study of fulvestrant and abemaciclib in hormone receptor positive advanced or recurrent endometrial Cancer.
E. Eleftherakis-Papaiakovou

14.50-15.20
LBA 5500 | Final Results of BRUOG354: A Randomized Phase II Trial of Nivolumab alone or in combination with Ipilimumab for People with Ovarian and other Extrarenal Clear Cell Carcinomas
Abstract 5506 | Phase II randomized multi-centre study of neoadjuvant olaparib in patients with platinum sensitive relapsed high grade serous ovarian cancer: The NEO trial.
Abstract 5510 | Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A).
M. Rovithi

15.20-15.40 Discussant N. Kaparelou

Chairs: A. Koumarianou, M. Nikolaou

15.40-16.00
LBA 8505 | Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.
LBA 4 | Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study.
E-G. Fergadis

16.00-16.20
LBA 8503 | Lorlatinib vs crizotinib in treatment-naïve patients with dvanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.
Abstract 8509 | KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
O. Fiste

16.20-16.40 Discussant A. Grivas

Chairs: A. Kotsakis, K. Tsapakidis

16.40-17.00
Abstract 8506 | NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC).
LBA 8002 | BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM) - Results from the ETOP 13-18 trial.
D. Stefanou

17.00-17.20
Abstract 8015 | DeLLphi-301: Tarlatamab phase 2 trial in small cell lung cancer (SCLC) - Efficacy and safety analyzed by presence of brain metastasis.
LBA 5 | ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)
E. Karatrasoglou

17.20-17.40 Discussant A. Kyriazoglou

Chairs: K. Koutsoukos, P. Koinis

18.00-18.30
Abstract 5003 | Health-related quality of life and pain in a phase 3 study of [177Lu]Lu-PSMA-617 in taxane-naïve patients with metastatic castration-resistant prostate cancer (PSMAfore).
Abstract 5010 | A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC).
Abstract 10500 | Effect of polygenic risk score for clinically significant prostate cancer in a screening program: The BARCODE 1 study results.
T. Tegos

18.30-18.50
Abstract 5009 | A phase II trial of pembrolizumab plus platinum-based chemotherapy as first-line systemic therapy in advanced penile cancer: HERCULES (LACOG 0218) trial. Abstract 4502 | Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).
E. Christakou

18.50-19.10
Abstract 4509 | Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial.
Abstract 4508 | Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial.
N. Cholis

19.10-19.30 Discussant E. Lianos

Aidarinis V.
Resident of Medical Oncology University Hospital of Larissa
Ardavanis – Loukeris G.
Resident of Οncology, Saint Savvas General Anticancer Oncological Hospital of Athens
Asimakopoulou N.
MD, PhD, Medical Oncologist, 1st Oncology Dpt, Metropolitan General, Athens, Greece
Avgoustidou M.
MD, ehem.OÄ, FÄ, German Board certified Oncologist / Hematologist Specialized in Palliative Care, Athens Medical Group, Athens, Greece
Bafaloukos D.
Medical Oncologist, Director A’ Oncology Dpt., Metropolitan Hospital of Athens, Professor em. - University of W. Attica, Greece
Barbounis V.
Medical Oncologist, Director, 5th Oncology Clinic, IASO Hospital, Athens, Greece
Boutis A.
Consultant Medical Oncologist, Director, 3rd Med. Oncology Dept., “Theagenio” Anticancer Hospital of Thessaloniki, Greece
Chantzara E.
Medical Oncologist, University Hospital of Larissa
Cholis N.
Medical Oncologist, General Hospital of Rhodes, Greece
Christakou E.
MD, Medical Oncology Resident, Metaxa Memorial Center Hospital, Piraeus
Drizou M.
Medical Oncologist - Consultant, Chios General Hospital, Chios, Greece
Duran Moreno J.
MD, MSc, Παθολόγος - Ογκολόγος, Εξωτερικός Συνεργάτης Ιατρικού Κέντρου Αθηνών
Eleftherakis-Papaiakovou E.
Medical Oncologist, MD, MSc, PhD, Consultant, Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece
Fergadis E. G.
Medical Oncologist, Consultant, “Metaxa” Hospital, Piraeus, Greece
Fiste O.
MD, MSc, PhD, Medical Oncologist, 3rd Department of Internal Medicine and the Affiliated Laboratory, School of Medicine, National and Kapodistrian University of Athens, “Sotiria” Hospital, Athens, Greece
Gogas H.
Professor of Medical Oncology, 1st Department of Medicine, Laiko Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
Grivas A.
MD, Medical Oncologist Consultant, 2nd department of Medical Oncology, “Agios Savvas” Anticancer Hospital, Athens, Greece
Kalapanida D.
MD, PhD, Medical Oncologist, 3rd Medical Oncology Department, Hygeia Hospital, Athens
Kaparelou M.
Medical Oncologist, Dept of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra Hospital
Karatrasoglou E.
MD, MSc, PhD, Medical Oncology Resident Doctor
Katsaounis P.
MD, MSc, Medical Oncologist, Metropolitan General Hospital, Athens, Greece
Koinis F.
MD, PhD, Assistant Professor of Medical Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece
Kontopodis Ε.
MD, Medical Oncologist, Venizeleion General Hospital of Heraklion, Crete, Greece
Kosmas Ch.
MD, Consultant & Head: Department of Medical Oncology & Hematopoietic Cell Transplant Unit, “Metaxa” Cancer Hospital, Piraeus, Greece
Kotteas Ε.
Associate Professor of Oncology, National & Kapodistrian University of Athens
Koutras Α.
Associate Professor of Medical Oncology, Medical School, University of Patras, Head of the Division of Oncology, Department of Medicine, University Hospital of Patras, Greece
Koutsoukos K.
MD, MCs, Medical Oncologist, Alexandra Hospital, National Kapodistrian University of Athens, Eugenideio Hospital, Athens
Kyriazoglou A
MD, PhD, Medical Oncologist, National & Kapodistrian University of Athens, 2nd Propaedeutic Department of Medicine, Attikon University Hospital, Athens, Greece
Labropoulos S.
Assistant Director, 3rd Medical Oncology Department, Hygeia Hospital, Athens
Laskarakis A.
Professor, Head of the Nursing Department, International Hellenic University, Thessaloniki, Greece
Lavdaniti M.
Professor - Nursing Department, International Hellenic University, Thessaloniki
Machairas N.
MD, PhD, FACS, Assistant Professor of Surgery, 2nd Department of Propaedeutic Surgery, General Hospital Laiko, National and Kapodistrian University of Athens, Athens, Greece
Mala N.
Medical Oncologist, University Hospital of Heraklion, Grete
Nikolaidi A.
Medical Oncologist, Deputy Director Oncology Department, MITERA Hospital, Athens, Greece
Nikolaou Μ.
MD, MSc, PhD, Medical Oncologist, Anti - Cancer Hospital Agios Savvas, Athens, Greece
Ntola Ch.
RN, Bsc, Msc, Oncology Nurse in Euroclinic Athens Hospital, Athens
Papadimitriou C.
Professor of Medical Oncology, Aretaieion University Hospital, School of Medicine, National and Kapodistrian Univerity of Athens, Athens, Greece
Papadopoulos V.
MD, Oncologist, Consultant, Department of Oncology, University Hospital, Larisa, Greece
Papageorgiou D.
Assistant Professor University of Peloponnese, Head Nurse Oncology Unit Euroclinic Athens, President of Hellenic Oncology Nursing Society, Athens, Greece
Papaxoinis G.
MD, PhD, Consultant Medical Oncologist, Agios Savvas Anticancer Hospital, Athens, Greece
Rapti K.
MD, MSc, Consultant Medical Oncologist, 251 General Airforces Hospital, Athens, Greece
Razis E.
MD, PhD, Medical Oncologist, Director, 3rd Oncology Department, Hygeia Hospital, Director, Contemporary Oncology Team, Athens
Rigakos G.
MD, MSc, Medical Oncologist, 3rd Oncology Department Contemporary Oncology Team, Hygeia Hospital, Athens, Greece
Saloustros E.
MD, PhD, Associate Professor of Medical Oncology, School of Medicine, University of Thessaly, General University Hospital of Larissa, Larissa, Greece
Samaras I.
MD, Medical Oncologist, University Hospital of Larissa, Greece
Stefanou D.
MD, PhD, Mesical Oncologist, 1rst Department of Internal Medicine, Laiko General Hospital, Athens, Greece
Stribakos A.
Medical Oncologist, Director of 5th Internal Medicine - Oncology Clinic, Hygeia Hospital, Athens, Greece
Talagani S.
Medical Oncology Resident, Agios Savvas General Anticancer Hospital of Athens
Tegos Th.
MD, PhD, Medical Oncologist, Evangelismos General Hospital, Athens, Greece
Theochari M.
Medical Oncologist, First Department of Medicine, Laiko General Hospital, Athens, Greece
Tsoukalas N.
MD, MSc, PhD, Medical Oncologist, MSc in Bioinformatics, Director, Oncology Department, Veterans Hospital (417 NIMTS), Consultant, Henry Dunant Hospital Center, Athens Greece
Tzovaras A.
Medical Oncologist Consultant, Agios Savvas Anticancer Hospital, Athens

Technical Support is available:
- everyday 09:00-17:00
- at the day of the event 09:00-21:00
For Technical Support please contact us:
Phone: +30 210 72 40 039
Email: support@livetime.gr

Event Details
Sponsors